Sunitinib is the registered treatment for first-line therapy of metastatic clear-cell
carcinoma of the kidney.Data from the Expanded Access Study have shown activity also in
non-clear cell renal cancer (NCCRC). The aim of this study is to prospectively evaluate the
anti-tumor activity and safety of sunitinib as a first-line therapy in metastatic NCCRC
patients.